Article Information
History
- December 15, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Raches Ella, MBBS, MS1,*,
- Krishna Mohan Vadrevu, PhD1,
- Harsh Jogdand, PhD.1,
- Sai Prasad, MSc1,
- Siddharth Reddy, MSc1,
- Vamshi Sarangi, BSc1,
- Brunda Ganneru, PhD1,
- Gajanan Sapkal, PhD2,
- Pragya Yadav, PhD2,
- Priya Abraham, MD, PhD2,
- Samiran Panda, MD3,
- Nivedita Gupta, MD3,
- Prabhakar Reddy, MD4,
- Savita Verma, MD5,
- Sanjay Kumar Rai, MD6,
- Chandramani Singh, MD7,
- Sagar Vivek Redkar, MD8,
- Chandra Sekhar Gillurkar, MD9,
- Jitendra Singh Kushwaha, MD10,
- Satyajit Mohapatra, MD11,
- Venkat Rao, MD12,
- Randeep Guleria, MD6,
- Krishna Ella, PhD1 and
- Balram Bhargava, MD3
- 1Bharat Biotech, Hyderabad, India
- 2Indian Council of Medical Research-National Institute of Virology, Pune, India
- 3Indian Council of Medical Research, New Delhi, India
- 4Nizams Institute of Medical Sciences, Hyderabad, India
- 5Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India
- 6All India Institute of Medical Sciences, New Delhi, India
- 7All India Institute of Medical Sciences, Patna, India
- 8Redkar Hospital, Dargalim, India
- 9Gillurkar Hospital, Nagpur, India
- 10Prakhar Hospital, Kanpur, India
- 11SRM Hospital and Research Centre, Kattankulathur, India
- 12Institute of Medical Sciences and SUM Hospital, Bhubaneswar, India
- ↵*Corresponding author; email: rachesella{at}gmail.com
Posted December 15, 2020.
A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152
